KDR and neoplasm: In recent years, many preclinical models and clinical trials have demonstrated that combining anti‐angiogenic agents (including tyrosine kinase inhibitors and anti‐VEGFR monoclonal antibodies) with ICIs can modulate the tumor microenvironment and immunometabolism and increase PD‐L1 expression in tumors, thus leading to a strong and sustained antitumour effect.32, 33, 34